China Resources Pharmaceutical Group Ltd.
3320
Rank in Stocks
#4247
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Share Price
$0.5954966
Market Cap
$3.74B
Change (1 day)
1.09%
Change (1 year)
-2.61%
Country
HK
Trade China Resources Pharmaceutical Group Ltd. (3320)
Category
Healthcare
P/E ratio for China Resources Pharmaceutical Group Ltd. (3320)
P/E ratio as of October 2026 TTM: 6.24
According to China Resources Pharmaceutical Group Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 6.24. At the end of 2023 the company had a P/E ratio of 8.36.
P/E ratio history for China Resources Pharmaceutical Group Ltd. from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 6.24 | -37.85% |
| 2024 | 10.04 | 20.11% |
| 2023 | 8.36 | -26.28% |
| 2022 | 11.34 | 56.69% |
| 2021 | 7.24 | -19.56% |
| 2020 | 9.00 | -34.91% |
| 2019 | 13.83 | -13.08% |
| 2018 | 15.91 | -12.89% |
| 2017 | 18.26 | 19.85% |
| 2016 | 15.24 | 4.10% |
| 2015 | 14.64 | -30.37% |
| 2014 | 21.02 | -0.24% |
| 2013 | 21.07 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 24.47 | 292.20% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 223.52 | 3,482.04% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.